A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity

mBio

Volumn 6, Issue 2, 2015, Pages

  Gebhart, Dana ^a   Lok, Stephen ^a   Clare, Simon ^b   Tomas, Myreen ^c,d   Stares, Mark ^b   Scholl, Dean ^a   Donskey, Curtis J ^c,d   Lawley, Trevor D ^b   Govoni, Gregory R ^a  

^a AvidBiotics Corporation   (United States)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIOCIN; BINDING PROTEIN; CD4 ANTIGEN; PROTEIN DIFFOCIN; PROTEIN RBP; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENOME; BACTERIAL SPORE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE INFECTION; FEMALE; INOCULATION; INTESTINE FLORA; MALE; MOUSE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; PROPHAGE; PROTEIN ANALYSIS; PROTEIN TARGETING; SPECIES DIVERSITY; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS FAECIUM; ANIMAL; C57BL MOUSE; CLOSTRIDIUM INFECTIONS; DRUG EFFECTS; GASTROINTESTINAL TRACT; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIOLOGY; ORAL DRUG ADMINISTRATION;

CLOSTRIDIUM DIFFICILE; ENTEROCOCCUS FAECIUM; MUS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIOCINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; GASTROINTESTINAL TRACT; MALE; MICE, INBRED C57BL;

EID: 84928409059     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.02368-14     Document Type: Article

References (63)

1. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA.
2. See I, Mu Y, Cohen J, Beldavs ZG, Winston LG, Dumyati G, Holzbauer S, Dunn J, Farley MM, Lyons C, Johnston H, Phipps E, Perlmutter R, Anderson L, Gerding DN, Lessa FC. 2014. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis 58: 1394–1400. http://dx.doi.org/10.1093/cid/ciu125.
3. Tickler IA, Goering RV, Whitmore JD, Lynn AN, Persing DH, Tenover FC, Healthcare Associated Infection Consortium. 2014. Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States: 2011–2013. Antimicrob Agents Chemother 58:4214–4218. http://dx.doi.org/10.1128/AAC.02775-13.
4. He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, Connor TR, Harris SR, Fairley D, Bamford KB, D’Arc S, Brazier J, Brown D, Coia JE, Douce G, Gerding D, Kim HJ, Koh TH, Kato H, Senoh M, Louie T, Michell S, Butt E, Peacock SJ, Brown NM, Riley T, Songer G, Wilcox M, Pirmohamed M, Kuijper E, Hawkey P, Wren BW, Dougan G, Parkhill J, Lawley TD. 2013. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 45: 109–113. http://dx.doi.org/10.1038/ng.2478.
5. Figueroa I, Johnson S, Sambol SP, Goldstein EJC, Citron DM, Gerding DN. 2012. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis 55(Suppl 2):S104–S109. http://dx.doi.org/10.1093/cid/cis357.
6. Petrella LA, Sambol SP, Cheknis A, Nagaro K, Kean Y, Sears PS, Babakhani F, Johnson S, Gerding DN. 2012. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 55:351–357. http://dx.doi.org/10.1093/cid/cis430.
7. Gerding D, Muto C, Owens R, Jr. 2008. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 46(Suppl 1):S43–S49. http://dx.doi.org/10.1086/521861.
8. Dubberke ER, Butler AM, Yokoe DS, Mayer J, Hota B, Mangino JE, Khan YM, Popovich KJ, Fraser VJ. 2010. Multicenter study of Clostridium difficile infection rates from 2000 to 2006. Infect Control Hosp Epidemiol 31:1030–1037. http://dx.doi.org/10.1086/656245.
9. Blaser M. 2011. Antibiotic overuse: stop the killing of beneficial bacteria. Nature 476:393–394. http://dx.doi.org/10.1038/476393a.
10. Blaser MJ, Falkow S. 2009. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol 7:887–894. http://dx.doi.org/10.1038/nrmicro2245.
11. Dethlefsen L, McFall-Ngai M, Relman DA. 2007. An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 449:811–818. http://dx.doi.org/10.1038/nature06245.
12. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O. 2013. Antibiotic resistance-the need for global solutions. Lancet Infect Dis 13:1057–1098. http://dx.doi.org/10.1016/S1473-3099(13)70318-9.
13. Britton RA, Young VB. 2014. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology 146: 1547–1553. http://dx.doi.org/10.1053/j.gastro.2014.01.059.
14. Gebhart D, Williams SR, Bishop-Lilly KA, Govoni GR, Willner KM, Butani A, Sozhamannan S, Martin D, Fortier LC, Scholl D. 2012. Novel high-molecular-weight, R-type bacteriocins of Clostridium difficile. J Bacteriol 194:6240–6247. http://dx.doi.org/10.1128/JB.01272-12.
15. Nakayama K, Takashima K, Ishihara H, Shinomiya T, Kageyama M, Kanaya S, Ohnishi M, Murata T, Mori H, Hayashi T. 2000. The R-type pyocin of Pseudomonas aeruginosa is related to P2 phage, and the F-type is related to lambda phage. Mol Microbiol 38:213–231. http://dx.doi.org/10.1046/j.1365-2958.2000.02135.x.
16. Michel-Briand Y, Baysse C. 2002. The pyocins of Pseudomonas aeruginosa. Biochimie 84:499–510. http://dx.doi.org/10.1016/S0300-9084(02)01422-0.
17. Scholl D, Cooley M, Williams SR, Gebhart D, Martin D, Bates A, Mandrell R. 2009. An engineered R-type pyocin is a highly specific and sensitive bactericidal agent for the foodborne pathogen Escherichia coli O157:H7. Antimicrob Agents Chemother 53:3074–3080. http://dx.doi.org/10.1128/AAC.01660-08.
18. Kageyama M, Ikeda K, Egami F. 1964. Studies of A pyocin. III. Biological properties of the pyocin. J Biochem 55:59–64.
19. Scholl D, Gebhart D, Williams SR, Bates A, Mandrell R. 2012. Genome sequence of E. coli O104:H4 leads to rapid development of a targeted antimicrobial agent against this emerging pathogen. PLoS One 7:e33637. http://dx.doi.org/10.1371/journal.pone.0033637.
20. Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, Lawley TD, Sebaihia M, Quail MA, Rose G, Gerding DN, Gibert M, Popoff MR, Parkhill J, Dougan G, Wren BW. 2009. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol 10:R102. http://dx.doi.org/10.1186/gb-2009-10-9-r102.
21. Williams SR, Gebhart D, Martin DW, Scholl D. 2008. Retargeting R-type pyocins to generate novel bactericidal protein complexes. Appl Environ Microbiol 74:3868–3876. http://dx.doi.org/10.1128/AEM.00141-08.
22. Bachmanov AA, Tordoff MG, Beauchamp GK. 1996. Ethanol consumption and taste preferences in C57BL/6ByJ and 129/J mice. Alcohol Clin Exp Res 20:201–206. http://dx.doi.org/10.1111/j.1530-0277.1996.tb01630.x.
23. Bachmanov AA, Tordoff MG, Beauchamp GK. 2001. Sweetener preference of C57BL/6ByJ and 129P3/J mice. Chem Senses 26:905–913. http://dx.doi.org/10.1093/chemse/26.7.905.
24. Lawley TD, Clare S, Walker AW, Goulding D, Stabler RA, Croucher N, Mastroeni P, Scott P, Raisen C, Mottram L, Fairweather NF, Wren BW, Parkhill J, Dougan G. 2009. Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun 77: 3661–3669. http://dx.doi.org/10.1128/IAI.00558-09.
25. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, Raisen C, Goulding D, Rad R, Schreiber F, Brandt C, Deakin LJ, Pickard DJ, Duncan SH, Flint HJ, Clark TG, Parkhill J, Dougan G. 2012. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 8:e1002995. http://dx.doi.org/10.1371/journal.ppat.1002995.
26. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, Ubeda C, Xavier J, Pamer EG. 2012. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun 80: 62–73. http://dx.doi.org/10.1128/IAI.05496-11.
27. Nagaro KJ, Phillips ST, Cheknis AK, Sambol SP, Zukowski WE, Johnson S, Gerding DN. 2013. Non-toxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic BI/NAP1/027 C. difficile. Antimicrob Agents Chemother 57:5266–5270. http://dx.doi.org/10.1128/AAC.00580-13.
28. Crawford T, Huesgen E, Danziger L. 2012. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am J Health Syst Pharm 69:933–943. http://dx.doi.org/10.2146/ajhp110371.
29. Swanson RN, Hardy DJ, Shipkowitz NL, Hanson CW, Ramer NC, Fernandes PB, Clement JJ. 1991. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother 35:1108–1111. http://dx.doi.org/10.1128/AAC.35.6.1108.
30. Jump RL, Polinkovsky A, Hurless K, Sitzlar B, Eckart K, Tomas M, Deshpande A, Nerandzic MM, Donskey CJ. 2014. Metabolomics analysis identifies intestinal microbiota-derived biomarkers of colonization resistance in clindamycin-treated mice. PLoS One 9:e101267. http://dx.doi.org/10.1371/journal.pone.0101267.
31. Pultz NJ, Donskey CJ. 2005. Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice. Antimicrob Agents Chemother 49:3529–3532. http://dx.doi.org/10.1128/AAC.49.8.3529-3532.2005.
32. Stiefel U, Pultz NJ, Helfand MS, Donskey CJ. 2004. Increased susceptibility to vancomycin-resistant enterococcus intestinal colonization persists after completion of anti-anaerobic antibiotic treatment in mice. Infect Control Hosp Epidemiol 25:373–379. http://dx.doi.org/10.1086/502408.
33. Abujamel T, Cadnum JL, Jury LA, Sunkesula VC, Kundrapu S, Jump RL, Stintzi AC, Donskey CJ. 2013. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. PLoS One 8:e76269. http://dx.doi.org/10.1371/journal.pone.0076269.
34. Ananthakrishnan AN. 2011. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 8:17–26. http://dx.doi.org/10.1038/nrgastro.2010.190.
35. Clements AC, Magalhães RJ, Tatem AJ, Paterson DL, Riley TV. 2010. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 10:395–404. http://dx.doi.org/10.1016/S1473-3099(10)70080-3.
36. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH. 2010. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 23:529–549. http://dx.doi.org/10.1128/CMR.00082-09.
37. Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A, Gardam M, McGeer A, Hutchinson J, Moore D, Kelly S. 2010. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 50:194–201. http://dx.doi.org/10.1086/649213.
38. Lawley TD, Clare S, Deakin LJ, Goulding D, Yen JL, Raisen C, Brandt C, Lovell J, Cooke F, Clark TG, Dougan G. 2010. Use of purified Clostridium difficile spores to facilitate evaluation of health care disinfection regimens. Appl Environ Microbiol 76:6895–6900. http://dx.doi.org/10.1128/AEM.00718-10.
39. Wilcox MH, Fraise AP, Bradley CR, Walker J, Finch RG. 2011. Sporicides for Clostridium difficile: the devil is in the detail. J Hosp Infect 77: 187–188. http://dx.doi.org/10.1016/j.jhin.2010.10.017.
40. Deakin LJ, Clare S, Fagan RP, Dawson LF, Pickard DJ, West MR, Wren BW, Fairweather NF, Dougan G, Lawley TD. 2012. The Clostridium difficile spo0A gene is a persistence and transmission factor. Infect Immun 80:2704–2711. http://dx.doi.org/10.1128/IAI.00147-12.
41. Marsh JW, Arora R, Schlackman JL, Shutt KA, Curry SR, Harrison LH. 2012. Association of relapse of Clostridium difficile disease with BI/NAP1/027. J Clin Microbiol 50:4078–4082. http://dx.doi.org/10.1128/JCM.02291-12.
42. Tenover FC, Akerlund T, Gerding DN, Goering RV, Boström T, Jonsson AM, Wong E, Wortman AT, Persing DH. 2011. Comparison of strain typing results for Clostridium difficile isolates from North America. J Clin Microbiol 49:1831–1837. http://dx.doi.org/10.1128/JCM.02446-10.
43. Van den Berg RJ, Ameen HA, Furusawa T, Claas EC, van der Vorm ER, Kuijper EJ. 2005. Coexistence of multiple PCR-ribotype strains of Clostridium difficile in faecal samples limits epidemiological studies. J Med Microbiol 54:173–179. http://dx.doi.org/10.1099/jmm.0.45825-0.
44. Eyre DW, Walker AS, Griffiths D, Wilcox MH, Wyllie DH, Dingle KE, Crook DW, Peto TE. 2012. Clostridium difficile mixed infection and reinfection. J Clin Microbiol 50:142–144. http://dx.doi.org/10.1128/JCM.05177-11.
45. Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL, Donskey CJ. 2007. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 45:992–998. http://dx.doi.org/10.1086/521854.
46. Eyre DW, Griffiths D, Vaughan A, Golubchik T, Acharya M, O’Connor L, Crook DW, Walker AS, Peto TE. 2013. Asymptomatic Clostridium difficile colonisation and onward transmission. PLoS One 8:e78445. http://dx.doi.org/10.1371/journal.pone.0078445.
47. Alasmari F, Seiler SM, Hink T, Burnham CA, Dubberke ER. 2014. Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clin Infect Dis 59:216–222. http://dx.doi.org/10.1093/cid/ciu258.
48. Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ, Hernandez RD, Lederman MM, Huang Y, Somsouk M, Deeks SG, Hunt PW, Lynch SV, McCune JM. 2013. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 5:193ra191. http://dx.doi.org/10.1126/scitranslmed.3006438.
49. Xuan C, Shamonki JM, Chung A, DiNome ML, Chung M, Sieling PA, Lee DJ. 2014. Microbial dysbiosis is associated with human breast cancer. PLoS One 9:e83744. http://dx.doi.org/10.1371/journal.pone.0083744.
50. Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, Schwager E, Knights D, Song SJ, Yassour M, Morgan XC, Kostic AD, Luo C, González A, McDonald D, Haberman Y, Walters T, Baker S, Rosh J, Stephens M, Heyman M, Markowitz J, Baldassano R, Griffiths A, Sylvester F, Mack D, Kim S, Crandall W, Hyams J, Huttenhower C, Knight R, Xavier RJ. 2014. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 15:382–392. http://dx.doi.org/10.1016/j.chom.2014.02.005.
51. Cox LM, Yamanishi S, Sohn J, Alekseyenko AV, Leung JM, Cho I, Kim SG, Li H, Gao Z, Mahana D, Zárate Rodriguez JG, Rogers AB, Robine N, Loke P, Blaser MJ. 2014. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 158:705–721. http://dx.doi.org/10.1016/j.cell.2014.05.052.
52. Donskey CJ, Hanrahan JA, Hutton RA, Rice LB. 1999. Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis 180: 384–390. http://dx.doi.org/10.1086/314874.
53. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue Y-K, OPT-80-003 Clinical Study Group. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422–431. http://dx.doi.org/10.1056/NEJMoa0910812.
54. Bernard R, Marquis KA, Rudner DZ. 2010. Nucleoid occlusion prevents cell division during replication fork arrest in Bacillus subtilis. Mol Microbiol 78:866–882. http://dx.doi.org/10.1111/j.1365-2958.2010.07369.x.
55. Youngman PJ, Perkins JB, Losick R. 1983. Genetic transposition and insertional mutagenesis in Bacillus subtilis with Streptococcus faecalis transposon Tn917. Proc Natl Acad Sci U S A 80:2305–2309. http://dx.doi.org/10.1073/pnas.80.8.2305.
56. Liu S, Endo K, Ara K, Ozaki K, Ogasawara N. 2008. Introduction of marker-free deletions in Bacillus subtilis using the AraR repressor and the ara promoter. Microbiology 154:2562–2570. http://dx.doi.org/10.1099/mic.0.2008/016881-0.
57. Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA, III, Smith HO. 2009. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 6:343–345. http://dx.doi.org/10.1038/nmeth.1318.
58. Yamamoto KR, Alberts BM, Benzinger R, Lawhorne L, Treiber G. 1970. Rapid bacteriophage sedimentation in the presence of polyethylene glycol and its application to large-scale virus purification. Virology 40:734–744. http://dx.doi.org/10.1016/0042-6822(70)90218-7.
59. Bachmanov AA, Reed DR, Tordoff MG, Price RA, Beauchamp GK. 1996. Intake of ethanol, sodium chloride, sucrose, citric acid, and quinine hydrochloride solutions by mice: a genetic analysis. Behav Genet 26: 563–573. http://dx.doi.org/10.1007/BF02361229.
60. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Peña AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. 2010. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7:335–336. http://dx.doi.org/10.1038/nmeth.f.303.
61. Lozupone CA, Hamady M, Kelley ST, Knight R. 2007. Quantitative and qualitative beta diversity measures lead to different insights into factors that structure microbial communities. Appl Environ Microbiol 73: 1576–1585. http://dx.doi.org/10.1128/AEM.01996-06.
62. Lozupone C, Knight R. 2005. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol 71: 8228–8235. http://dx.doi.org/10.1128/AEM.71.12.8228-8235.2005.
63. Lozupone C, Hamady M, Knight R. 2006. UniFrac—an online tool for comparing microbial community diversity in a phylogenetic context. BMC Bioinformatics 7:371. http://dx.doi.org/10.1186/1471-2105-7-371